Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Regen BioPharma (RGBPP) over the last 13 years, with Q4 2025 value amounting to $29991.0.

  • Regen BioPharma's Change in Accured Expenses fell 3001.26% to $29991.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $160451.0, marking a year-over-year increase of 25629.65%. This contributed to the annual value of $173312.0 for FY2025, which is 76890.6% up from last year.
  • According to the latest figures from Q4 2025, Regen BioPharma's Change in Accured Expenses is $29991.0, which was down 3001.26% from $63981.0 recorded in Q3 2025.
  • Over the past 5 years, Regen BioPharma's Change in Accured Expenses peaked at $102107.0 during Q1 2021, and registered a low of -$17936.0 during Q1 2024.
  • In the last 5 years, Regen BioPharma's Change in Accured Expenses had a median value of $25820.5 in 2025 and averaged $32384.6.
  • As far as peak fluctuations go, Regen BioPharma's Change in Accured Expenses crashed by 24841.54% in 2024, and later surged by 239633.24% in 2025.
  • Regen BioPharma's Change in Accured Expenses (Quarter) stood at $6036.0 in 2021, then soared by 187.59% to $17359.0 in 2022, then grew by 2.34% to $17765.0 in 2023, then soared by 141.22% to $42852.0 in 2024, then plummeted by 30.01% to $29991.0 in 2025.
  • Its last three reported values are $29991.0 in Q4 2025, $63981.0 for Q3 2025, and $21650.0 during Q2 2025.